Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Financial News

Amicus raises $90 million on back of Amigal

November 20, 2014 2:37 AM UTC

Amicus Therapeutics Inc. (NASDAQ:FOLD) raised $90 million to commercialize its Amigal migalastat to treat Fabry's disease after pricing a follow-on of 13.9 million shares at $6.50 per share on Wednesday.

Amicus intends to meet with European regulators by year end and with FDA in early 2015 to discuss a regulatory path for the compound. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article